

Date: 14th November, 2019

To,

EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Subject: REVISED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2019.
SYMBOL: AJOONI


Dear Sir/Madam,

We hereby submitting the revised financial results for the half year ended 30th September, 2019 which includes Cash Flow Statement for the half year ended 30th September, 2019.

Kindly take the same on record

Thanking You,
Yours Truly,

For Ajooni Biotech Limited


Jasjot Singh
Managing Director
DIN: 01937631



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on the Half Yearly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors,
Ajooni Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Ajooni Biotech Limited ("the Company") for the Half Year ended September 30, 2019 and year to date from April 01, 2019 to September 30, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") read with SEBI Circular No. CIR/CFD/CMDI /44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors in their meeting held on November 13, 2019, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mohali

Date: 13th Day of November, 2019

For Harjeet Parvesh & Company
Chartered Accountants

FRN: 0194374

CA Harjeet Singh

FCA

M.No 095466

UDIN: 19095466AAAAFJ4383



AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLC040162

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2019 (RS. IN LAKHS)


	PARTICULARS	Half Yearly			Yearly	
		30.09.2019 (Unaudited)	31.03.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (Audited)	31.03.2018 (Audited)
I	Revenue From Operations	1646.34	2145.75	1826.06	3971.81	4237.42
II	Other Income	14.12	32.33	1.53	33.86	22.00
III	TOTAL REVENUE (I + II)	1,660.46	2,178.08	1,827.59	4,005.67	4,259.42
IV	EXPENSES:					
	Cost of Material Consumed	1469.62	1697.13	1949.35	3646.48	3755.44
	Purchase of Stock-In-Trade	0.00	0.00	0.00	0.00	0.00
	Change In Inventories	-7.80	286.95	-286.23	0.72	13.48
	Finance Cost	13.41	6.32	4.39	10.71	34.07
	Employee Benefit Expenses	69.39	17.34	54.79	72.13	88.15
	Depreciation and amortization	15.92	29.63	14.19	43.82	45.55
	Other Expenses	79.31	113.79	70.53	184.32	273.93
	TOTAL EXPENSES	1,639.85	2,151.16	1,807.02	3,958.18	4,210.63
V	PROFIT/(LOSS) FROM OPERATION BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX (III-IV)	20.61	26.92	20.57	47.49	48.79
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	PROFIT/(LOSS) BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)	20.61	26.92	20.57	47.49	48.79
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	PROFIT/(LOSS) BEFORE TAX (VII-VIII)	20.61	26.92	20.57	47.49	48.79
X	TAX EXPENSE:					
	(1) Current Tax	0.00	11.75	0.00	11.75	13.08
	(2) Deferred Tax	0.00	-5.35	0.00	-5.35	-2.90
	(3) MAT Credit	0.00	0.00	0.00	0.00	0.00
XI	NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS (VII-VIII)	20.61	20.52	20.57	41.10	38.61
XII	NET PROFIT/(LOSS) FROM DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIII	TAX EXPENSE OF DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIV	NET PROFIT/(LOSS) FROM DISCONTINUING OPERATIONS (after Tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV	Profit/Loss for the period(XI+XIV)	20.61	20.52	20.57	41.10	38.61
XVI	NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13 + 14 + 15) *	20.61	20.52	20.57	41.10	38.61
XVII	Paid-up equity share capital (Face Value of the Share shall be indicated)	615.50	615.50	585.50	615.50	585.50
XVIII	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	600.96	508.86	508.86	508.86	63.89
XIX	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):					
	(1)BASIC	0.33	0.33	0.35	0.67	0.66
	(2)DILUTED	0.33	0.33	0.35	0.67	0.66
XX	Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):					
	(1)BASIC	0.33	0.33	0.35	0.67	0.66
	(2)DILUTED	0.33	0.33	0.35	0.67	0.66
	* Applicable in the case of consolidated results.					

Notes:

- Figures for the six months ended March 31, 2019 are balancing figures between audited figures in respect of full financial year and the published year to date figures up to the first half of the relevant year.
- The figures upto the end of the first half were only reviewed and were not audited.
- The above financial results of the company for the half year ended 30 September, 2019 have been reviewed by the audit committee and approved by the Board of directors at its meeting held on November 13, 2019.
- Segment Reporting is not applicable, since the company is involved in one segment only

For and on behalf of Board of Ajooni Biotech Limited

Place : Mohali
Date : 13.11.2019


 Jasjit Singh
 Director
 DIN: 01937631

AJOONI BIOTECH LIMITED

CIN : U85190PB2010PLC040162

STATEMENT OF ASSETS AND LIABILITIES

UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES (RS. IN LAKHS)

Particulars	AS ON 30.09.2019	AS ON 31.03.2019
	Unaudited	Audited
I. EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL	615.50	615.50
(B) RESERVES AND SURPLUS	622.03	600.96
(C) MONEY RECEIVED AGAINST SHARE WARRANTS	-	-
SUB-TOTAL - SHAREHOLDERS' FUNDS	1,237.53	1,216.46
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT		
(3) MINORITY INTEREST *		
(4) NON CURRENT LIABILITIES		
(A) LONG TERM BORROWINGS	30.43	16.01
(B) DEFERRED TAX LIABILITIES (NET)	-	-
(C) OTHER NON-CURRENT LIABILITIES	399.72	399.72
(D) LONG-TERM PROVISIONS	-	-
SUB-TOTAL - NON-CURRENT LIABILITIES	430.15	415.73
(5) CURRENT LIABILITIES		
(A) SHORT TERM BORROWINGS	207.33	50.27
(B) TRADE PAYABLE	151.44	73.71
(C) OTHER CURRENT LIABILITIES	87.79	56.42
(D) SHORT TERM PROVISIONS	0.62	12.39
SUB-TOTAL - CURRENT LIABILITIES	447.18	192.79
TOTAL EQUITY & LIABILITIES	2,114.86	1,824.98
II. ASSETS		
(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS	104.33	102.20
(B) GOODWILL ON CONSOLIDATION *		
(C) NON CURRENT INVESTMENTS	363.02	376.40
(D) DEFERRED TAX ASSETS (NET)	9.29	9.29
(E) LONG TERM LOANS & ADVANCES	111.72	111.72
(F) OTHER NON CURRENT ASSETS	42.21	42.21
SUB-TOTAL - NON-CURRENT ASSETS	630.57	641.82
(2) CURRENT ASSETS		
(A) CURRENT INVESTMENTS		
(B) INVENTORIES	506.00	506.89
(C) TRADE RECEIVABLES	805.52	483.33
(D) CASH AND CASH EQUIVALENTS	29.85	73.07
(E) SHORT TERM LOANS AND ADVANCES	142.91	119.86
(F) OTHER CURRENT ASSETS	0.00	-
SUB-TOTAL - CURRENT ASSETS	1484.29	1183.16
TOTAL-ASSETS	2,114.86	1,824.98

*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

For and on behalf of Board of Ajooni Biotech Limited

Place : Mohali

Date : 13.11.2019

Jasjot Singh

Director

DIN: 01937631

AJOONI BIOTECH LIMITED
Unaudited Standalone Cash flow Statement

(Amount Rs. In Lakhs)

	Particulars	For the half year ended 30th Sept, 2019	For the half year ended 30th Sept, 2018
A.	Cash flow from operating activities		
	Profit/(Loss) before tax	21.07	20.57
	Adjustments for:		
	Depreciation and amortisation	15.92	14.19
	Profit on Sale of Investments	-6.01	-
	Interest income	-7.20	-
	Interest expense	13.41	4.39
	Operating profit before working capital changes	37.19	39.15
	Adjustments for movement in:		
	Trade payables	77.73	38.91
	Provisions and other liabilities	19.60	-23.01
	Trade receivables	-322.19	-67.04
	Loans and advances and other assets	-23.05	-55.02
	Inventories	0.89	-286.23
	Cash generated from/(used in) operations	-209.83	-353.25
	Income taxes paid (including taxes deducted at source)	-	-
	Net cash generated from/(used in) operating activities	-209.83	-353.25
B	Cash flow from investing activities :		
	Purchase of fixed assets	-18.05	-13.51
	Interest received	7.20	-
	Movement in Investments	19.39	179.82
	Net cash (used in) investing activities	8.54	166.31
C	Cash flow from financing activities		
	Movement in long-term borrowings	14.42	-381.52
	Movement in short-term borrowings	157.06	61.00
	Interest paid	-13.41	-4.39
	Net cash (used in)/generated from financing activities	158.06	-324.91
	Net increase in cash and cash equivalents (A+B+C)	-43.23	-511.85
	Cash and cash equivalents as at 1st April	73.07	529.69
	Cash and cash equivalents as at 30th September	29.85	17.85

Notes:

a) The above cash flow statement has been prepared under the "Indirect Method" as set out in Accounting Standard 3 (AS-3) on "Cash flow statements" as specified under section 133 of Companies

b) Negative figures have been shown in brackets.

This is the cash flow statement referred to in our report of even date.

For and on behalf of Board of Ajooni Biotech Limited


Jasjit Singh
 Director
 DIN: 01937631

Place : Mohali

Date : 13.11.2019